Stockscreener 앱 받기
31.20
11.27%
3.16
전일 마감가:
$28.04
열려 있는:
$27.97
하루 거래량:
4.05M
Relative Volume:
2.20
시가총액:
$3.61B
수익:
-
순이익/손실:
$-507.65M
주가수익비율:
-6.7826
EPS:
-4.6
순현금흐름:
$-616.24M
1주 성능:
-1.27%
1개월 성능:
-55.33%
6개월 성능:
-72.73%
1년 성능:
-51.87%
1일 변동 폭
$27.80
$31.31
1주일 범위
$27.66
$34.11
52주 변동 폭
$27.66
$121.06
백스사이트 Stock (PCVX) Company Profile
명칭
Vaxcyte Inc
전화
650-837-0111
주소
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
PCVX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
31.20 | 3.61B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
백스사이트 Stock (PCVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 개시 | Goldman | Buy |
| 2023-12-07 | 개시 | Mizuho | Buy |
| 2023-04-18 | 개시 | TD Cowen | Outperform |
| 2023-01-03 | 재확인 | Needham | Buy |
| 2022-12-15 | 개시 | Guggenheim | Buy |
| 2022-11-17 | 개시 | BTIG Research | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-24 | 재개 | Jefferies | Buy |
| 2020-07-07 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 개시 | Needham | Buy |
모두보기
백스사이트 주식(PCVX)의 최신 뉴스
Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential - Insider Monkey
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason - MSN
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges By Investing.com - Investing.com South Africa
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges - Investing.com
InvestingPro Fair Value model correctly predicted Vaxcyte’s decline By Investing.com - Investing.com UK
Vaxcyte (NASDAQ:PCVX) Given New $137.00 Price Target at Bank of America - Defense World
(PCVX) Investment Analysis - news.stocktradersdaily.com
Vaxcyte (PCVX) Stock Falls 45% Despite Positive Vaccine Trial Re - GuruFocus
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI - Yahoo Finance
BofA lowers Vaxcyte price target, says selloff after infant data ‘overdone’ - TipRanks
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Vaxcyte stock sinks despite Phase II IPD vaccine trial success - Yahoo Finance
Vaxcyte stock up on results from mid-stage trial of its pneumococcal vaccine - MSN
Vaxcyte’s Promising Vaccine Potential and Market Expansion Drive Buy Rating - TipRanks
Goldman Sachs cuts Vaxcyte stock price target to $100 - Investing.com
Goldman Sachs cuts Vaxcyte stock price target to $100 By Investing.com - Investing.com UK
Vaxcyte’s Strong Phase 2 Data and Future Prospects Justify Buy Rating Despite Market Overreaction - TipRanks
Vaxcyte price target lowered to $90 from $140 at Needham - MSN
Vaxcyte sights set on next results after ‘big moment’ with PCV - BioWorld MedTech
Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (NASDAQ:PCVX) - Seeking Alpha
Sector Update: Health Care Stocks Higher Late Afternoon - MarketScreener
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (NASDAQ:PCVX) - Seeking Alpha
Jefferies maintains Buy on Vaxcyte stock, price target at $146 By Investing.com - Investing.com Canada
Vaxcyte’s VAX-24: Promising Infant Vaccine Results Amidst Investor Concerns - TipRanks
Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials - TipRanks
Vaxcyte falls as pneumococcal vaccine data fails to meet lofty investor expectations - TradingView
Jefferies maintains Buy on Vaxcyte stock, price target at $146 - Investing.com India
Daily Digest: Large Asian grocer T&T Supermarket to land in S.F.; Vaxcyte stock plunges - The Business Journals
Biotech Stocks Hammered After A Key FDA Official Resigns - Investor's Business Daily
Vaxcyte stock touches 52-week low at $33.19 amid market shifts - Investing.com
Vaxcyte VAX-24 Vaccine Data Missed Wall Street Expectations, But Fundamentally Still Positive, Mizuho Securities Says - MarketScreener
Guggenheim maintains Vaxcyte stock Buy rating, $160 target By Investing.com - Investing.com Canada
Vaxcyte reports topline results from VAX-24 infant Phase 2 dose-finding study - TipRanks
Vaxcyte plunges despite pneumonia shot results as Marks departure weighs (PCVX:NASDAQ) - Seeking Alpha
Sector Update: Health Care Stocks Fall Pre-Bell Monday - MarketScreener
Vaxcyte’s VAX-24 shows promise in infant vaccine study By Investing.com - Investing.com South Africa
Vaxcyte Announces Positive Phase 2 Results for VAX-24 - TipRanks
Guggenheim maintains Vaxcyte stock Buy rating, $160 target - Investing.com
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine - Benzinga
S&P 500 Futures Fall in Premarket Trading; Vaxcyte, Moderna Lag - Barron's
Vaxcyte's Pneumococcal Conjugate Vaccine Candidate Shows Substantial Immune Response in Infants - Marketscreener.com
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study - The Manila Times
Vaxcyte stock tumbles following Phase 2 study results By Investing.com - Investing.com Australia
Vaxcyte Announces Positive Topline Results From VAX-24 Infant Phase 2 Dose-Finding Study - MarketScreener
Vaxcyte stock tumbles following Phase 2 study results - Investing.com
Vaxcyte’s VAX-24 shows promise in infant vaccine study - Investing.com
Breakthrough: Vaxcyte's New Vaccine Shows Promise in Phase 2 Infant Trial - Stock Titan
Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now - Insider Monkey
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - GlobeNewswire
백스사이트 (PCVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
백스사이트 주식 (PCVX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
4.44%
자본화:
|
볼륨(24시간):